Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications
Autore:
Reff, ME; Heard, C;
Indirizzi:
Idec Pharmaceut Corp, San Diego, CA 92191 USA Idec Pharmaceut Corp San Diego CA USA 92191 Corp, San Diego, CA 92191 USA
Titolo Testata:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
fascicolo: 1, volume: 40, anno: 2001,
pagine: 25 - 35
SICI:
1040-8428(200110)40:1<25:AROMTR>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESPIRATORY SYNCYTIAL VIRUS; HUMANIZED MONOCLONAL-ANTIBODY; PHASE-I TRIAL; HUMAN-IMMUNODEFICIENCY-VIRUS; ENZYME PRODRUG THERAPY; IMMUNE-RESPONSE; FUSION PROTEIN; CANCER-THERAPY; B-CELLS; BRONCHOPULMONARY DYSPLASIA;
Keywords:
antibody-drug conjugates; bispecific antibodies; monoclonal antibodies; monoclonal antibody effector function; monoclonal antibody pharmacokinetics; single chain Fv;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
86
Recensione:
Indirizzi per estratti:
Indirizzo: Reff, ME Idec Pharmaceut Corp, 3010 Sci Pk Rd,POB 919080, San Diego, CA 92191 USA Idec Pharmaceut Corp 3010 Sci Pk Rd,POB 919080 San Diego CA USA 92191
Citazione:
M.E. Reff e C. Heard, "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications", CR R ONC H, 40(1), 2001, pp. 25-35

Abstract

Although monoclonal antibodies have high specificity, their usefulness in the clinic, especially against solid tumors, has been limited. This arises in part from the inability of antibody molecules to penetrate into the tumor and kill the tumor cells. In addition, natural cytotoxic effects of antibodies, mediated through complement or Fc receptors, may not be sufficient to kill malignant cells. This review will present some of the antibody modifications used to increase efficacy. Modified recombinant antibodies have been designed to be more cytotoxic (immunotoxins), to increase natural effector functions (bivalent antibodies, antibody-fusion molecules, multimeric antibodies, directed mutations in Fc region), or to pretarget cells for concentration of cytotoxic drugs. This review will also focus on engineering of smaller versions of antibodies that retain specificity (single chain Fvs, Fabs, Fab(2)s. minibodies. domain deleted antibodies) and have increased penetrability of solid tumors. Many of these antibody modifications may resultin antigenic compounds which can limit repeat administration, Clinical experiences will be highlighted if information is available. (C) 2001 ElsevierScience Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 09:28:47